Zentalis is a clinical-stage company developing azenosertib, an oral WEE1 inhibitor for platinum-resistant ovarian cancer whose tumors overexpress the protein Cyclin E1; it is not approved.
Zentalis' case rests on azenosertib, an oral WEE1 inhibitor, as the first targeted treatment for platinum-resistant ovarian cancer that overexpresses Cyclin E1, about half of such patients. FDA said the Cyclin E1-positive DENALI Part 2 population could support accelerated approval, depending on the data, and the integrated topline readout is expected in the first half of 2027. The readout moved from year-end 2026; cash of $174.6 million was guided to last into late 2027 before Zentalis raised $80.5 million in August.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: DENALI Part 2 supports an accelerated approval filing
Do response rates and durability in Cyclin E1-positive patients support an accelerated approval filing?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Zentalis expects integrated DENALI Part 2 data for azenosertib in Cyclin E1-positive ovarian cancer in the first half of 2027, after FDA said the population could support accelerated approval; Part 1b data showed median survival of 15.9 months in Cyclin E1-positive patients
WEE1 inhibitor seeks accelerated approval in biomarker-selected PROC; single-arm DENALI data must clear FDA's bar
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Breast and gynecologic cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
14 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.